vs
Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and Sarepta Therapeutics, Inc. (SRPT). Click either name above to swap in a different company.
Sarepta Therapeutics, Inc. is the larger business by last-quarter revenue ($369.6M vs $321.1M, roughly 1.2× MADRIGAL PHARMACEUTICALS, INC.). MADRIGAL PHARMACEUTICALS, INC. runs the higher net margin — -18.2% vs -111.5%, a 93.3% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs -42.1%). Sarepta Therapeutics, Inc. produced more free cash flow last quarter ($127.6M vs $-133.8M).
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
MDGL vs SRPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $321.1M | $369.6M |
| Net Profit | $-58.6M | $-412.2M |
| Gross Margin | — | — |
| Operating Margin | -18.6% | -111.4% |
| Net Margin | -18.2% | -111.5% |
| Revenue YoY | 210.8% | -42.1% |
| Net Profit YoY | 1.4% | -359.2% |
| EPS (diluted) | $-2.55 | $-3.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.1M | $369.6M | ||
| Q3 25 | $287.3M | $370.0M | ||
| Q2 25 | $212.8M | $513.1M | ||
| Q1 25 | $137.3M | $611.5M | ||
| Q4 24 | $103.3M | $638.2M | ||
| Q3 24 | $62.2M | $429.8M | ||
| Q2 24 | — | $360.5M | ||
| Q1 24 | $0 | $359.5M |
| Q4 25 | $-58.6M | $-412.2M | ||
| Q3 25 | $-114.2M | $-50.6M | ||
| Q2 25 | $-42.3M | $196.9M | ||
| Q1 25 | $-73.2M | $-447.5M | ||
| Q4 24 | $-59.4M | $159.0M | ||
| Q3 24 | $-107.0M | $33.6M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | $-147.5M | $36.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | 59.3% | ||
| Q2 25 | — | 70.3% | ||
| Q1 25 | 96.7% | 77.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 78.7% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.9% |
| Q4 25 | -18.6% | -111.4% | ||
| Q3 25 | -39.7% | -27.9% | ||
| Q2 25 | -22.2% | 22.5% | ||
| Q1 25 | -57.8% | -49.1% | ||
| Q4 24 | -64.8% | 25.3% | ||
| Q3 24 | -187.1% | 5.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | 9.7% |
| Q4 25 | -18.2% | -111.5% | ||
| Q3 25 | -39.8% | -13.7% | ||
| Q2 25 | -19.9% | 38.4% | ||
| Q1 25 | -53.4% | -73.2% | ||
| Q4 24 | -57.5% | 24.9% | ||
| Q3 24 | -172.0% | 7.8% | ||
| Q2 24 | — | 1.8% | ||
| Q1 24 | — | 10.0% |
| Q4 25 | $-2.55 | $-3.92 | ||
| Q3 25 | $-5.08 | $-0.50 | ||
| Q2 25 | $-1.90 | $1.89 | ||
| Q1 25 | $-3.32 | $-4.60 | ||
| Q4 24 | $-2.50 | $1.56 | ||
| Q3 24 | $-4.92 | $0.34 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | $-7.38 | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.7M | $939.6M |
| Total DebtLower is stronger | $339.9M | $829.0M |
| Stockholders' EquityBook value | $602.7M | $1.1B |
| Total Assets | $1.3B | $3.3B |
| Debt / EquityLower = less leverage | 0.56× | 0.73× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.7M | $939.6M | ||
| Q3 25 | $295.7M | $851.0M | ||
| Q2 25 | $186.2M | $800.1M | ||
| Q1 25 | $183.6M | $522.8M | ||
| Q4 24 | $100.0M | $1.4B | ||
| Q3 24 | $232.7M | $1.2B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | $622.5M | $1.4B |
| Q4 25 | $339.9M | $829.0M | ||
| Q3 25 | $339.8M | $140.5M | ||
| Q2 25 | $118.4M | — | ||
| Q1 25 | $118.0M | — | ||
| Q4 24 | $117.6M | $1.1B | ||
| Q3 24 | $117.1M | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | $116.1M | $1.2B |
| Q4 25 | $602.7M | $1.1B | ||
| Q3 25 | $625.7M | $1.3B | ||
| Q2 25 | $696.0M | $1.4B | ||
| Q1 25 | $710.6M | $1.1B | ||
| Q4 24 | $754.4M | $1.5B | ||
| Q3 24 | $777.2M | $1.2B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | $850.8M | $961.2M |
| Q4 25 | $1.3B | $3.3B | ||
| Q3 25 | $1.4B | $3.5B | ||
| Q2 25 | $1.0B | $3.7B | ||
| Q1 25 | $996.6M | $3.5B | ||
| Q4 24 | $1.0B | $4.0B | ||
| Q3 24 | $1.1B | $3.6B | ||
| Q2 24 | — | $3.4B | ||
| Q1 24 | $1.1B | $3.2B |
| Q4 25 | 0.56× | 0.73× | ||
| Q3 25 | 0.54× | 0.11× | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.16× | 0.74× | ||
| Q3 24 | 0.15× | 1.01× | ||
| Q2 24 | — | 1.14× | ||
| Q1 24 | 0.14× | 1.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-133.5M | $131.2M |
| Free Cash FlowOCF − Capex | $-133.8M | $127.6M |
| FCF MarginFCF / Revenue | -41.7% | 34.5% |
| Capex IntensityCapex / Revenue | 0.1% | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-307.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-133.5M | $131.2M | ||
| Q3 25 | $79.8M | $-14.6M | ||
| Q2 25 | $-47.1M | $261.3M | ||
| Q1 25 | $-88.9M | $-583.4M | ||
| Q4 24 | $-104.5M | $92.0M | ||
| Q3 24 | $-67.0M | $-70.7M | ||
| Q2 24 | — | $14.9M | ||
| Q1 24 | $-149.2M | $-242.1M |
| Q4 25 | $-133.8M | $127.6M | ||
| Q3 25 | $79.0M | $-37.5M | ||
| Q2 25 | — | $229.5M | ||
| Q1 25 | — | $-627.1M | ||
| Q4 24 | $-104.7M | $54.0M | ||
| Q3 24 | $-67.8M | $-108.0M | ||
| Q2 24 | — | $-14.2M | ||
| Q1 24 | $-149.5M | $-274.5M |
| Q4 25 | -41.7% | 34.5% | ||
| Q3 25 | 27.5% | -10.1% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | -102.5% | ||
| Q4 24 | -101.3% | 8.5% | ||
| Q3 24 | -109.0% | -25.1% | ||
| Q2 24 | — | -3.9% | ||
| Q1 24 | — | -76.4% |
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 0.3% | 6.2% | ||
| Q2 25 | 0.0% | 6.2% | ||
| Q1 25 | 0.0% | 7.1% | ||
| Q4 24 | 0.2% | 6.0% | ||
| Q3 24 | 1.3% | 8.7% | ||
| Q2 24 | — | 8.1% | ||
| Q1 24 | — | 9.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | -2.10× | ||
| Q2 24 | — | 2.31× | ||
| Q1 24 | — | -6.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MDGL
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 65% |
| Other | $76.0M | 24% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11% |
SRPT
| Pmo Products | $202.5M | 55% |
| Elevidys | $110.4M | 30% |
| Other | $56.7M | 15% |
